RTP Mobile Logo
Select Publications


Ansell SM. Checkpoint blockade in lymphoma. J Clin Oncol 2021;39(5):525-33. Abstract

Ansell SM et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2021;27(8):2190-9. Abstract

Caimi P et al. Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2. ASCO 2021;Abstract 7546.

Schuster SJ et al. Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). ASCO 2021;Abstract 7535.


Martin P et al. Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in US routine clinical practice.

ASCO 2021;Abstract 7504.

Mato AR et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet 2021;397(10277):892-901. Abstract

Phillips TJ et al. The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability. ASCO 2021;Abstract 7505.

Smith MR et al. ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS. ASCO 2021;Abstract 7503.


Allen PB et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 2021;137(10):1318-26. Abstract

Diefenbach CS et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol 2020;7(9):e660-70. Abstract

Herrera AF et al. SWOG S1826: A Phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma. ASH 2020;Abstract 2969.

Kuruvilla J et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). ASCO 2020;Abstract 8005.